We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy. X
1.855.6.PROSTATE

ACTIVE SURVEILLANCE OR IMMEDIATE TREATMENT?

OVER 50% of newly diagnosed men have low risk prostate cancer that is unlikely to spread1

Ask your doctor

YET A MAJORITY of them receive immediate aggressive treatment, which may lead to impotence and incontinence

DOWNLOAD QUESTIONS TO ASK YOUR DOCTOR

IS ONCOTYPE DX RIGHT FOR YOU?

Results from the Oncotype DX test changed treatment recommendations for 1 in 4 patients2

Is Oncotype DX right for you? take the quiz! TAKE THE QUIZ

SUPPORT YOUR LOVED ONE IN HIS JOURNEY

Discussion guide GET THE DOCTOR DISCUSSION GUIDE

Find resources to help support your loved one

Prostate Cancer Loved Ones

Hear how Deb helped her husband Dan decide his treatment plan

1 Cooperberg. 2010. JCO
2 Badani et al. 2014. SUO
  • © 2013-2020 Genomic Health, Inc., an Exact Sciences corporation.

Oncotype DX Legal Information

The information presented on this site is intended to provide patients with newly diagnosed prostate cancer, as well as their friends and family, an opportunity to learn how the information provided by the Oncotype DX Genomic Prostate Score can be used, along with other clinical measures, to help patients and their doctors make treatment decisions. Patients should consult their doctor to determine the best treatment decision for their individual disease.

National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Copyright © 2013-2020 Genomic Health, Inc., an Exact Sciences corporation. All rights reserved. Genomic Health, Oncotype, Oncotype DX, Genomic Prostate Score, and AR-V7 Nucleus Detect are registered trademarks of Genomic Health, Inc., an Exact Sciences corporation. MyProstateCancerTreatment.org is sponsored by Exact Sciences, a clinical laboratory that developed and offers the Oncotype DX test.